In gastric cancer, researchers have targeted LRP5 using the CRISPR/Cas9 knockout system, which led to a reduction in the proliferation of cancer cells in vitro and in vivo via cell cycle-associated gene inhibition [11]. This evidence concerns the gene LRP5 and cancer.